Overview

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Status:
RECRUITING

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of lusutrombopag combined with recombinant human thrombopoietin for the treatment of thrombocytopenia in patients with chronic liver disease destined to undergo elective invasive surgery.

Phase:

PHASE2

Details

Lead Sponsor:

Anhui Provincial Hospital

Treatments:

Thrombopoietin